- Home
- BAND vs SLS Comparison
BAND vs SLS Comparison
Compare BAND & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAND | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.9M | 924.5M |
| IPO Year | 2017 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BAND | SLS |
|---|---|---|
| Price | $63.79 | $7.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $24.50 | $10.00 |
| AVG Volume (30 Days) | 1.1M | ★ 11.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | $110.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.50 | $1.39 |
| 52 Week High | $75.98 | $9.51 |
Technical Indicators
Market Signals| Indicator | BAND | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 53.37 |
| Support Level | $14.27 | $3.72 |
| Resistance Level | N/A | $9.51 |
| Average True Range (ATR) | 5.94 | 0.77 |
| MACD | -1.50 | -0.22 |
| Stochastic Oscillator | 35.40 | 31.76 |
Price Performance
Historical ComparisonAbout BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.